Getting your player ready...
Shares of Clovis Oncology plunged nearly 42 percent on Monday after the Boulder-based firm announced it was ceasing the development of its pancreatic cancer program, which performed poorly in a pivotal study.
Shares of Clovis Oncology plunged nearly 42 percent on Monday after the Boulder-based firm announced it was ceasing the development of its pancreatic cancer program, which performed poorly in a pivotal study.
